CytomX Therapeutics (CTMX) Depreciation and Depletion (2016 - 2017)
CytomX Therapeutics (CTMX) reported Depreciation and Depletion of $400000.0 for Q4 2017, down 20.0% on a YoY basis from $500000.0 in Q4 2016, and up 8.7% quarter-over-quarter from $368000.0 in Q3 2017.
CytomX Therapeutics (CTMX) Depreciation and Depletion (2016 - 2017) Analysis & Trends
CytomX Therapeutics has reported Depreciation and Depletion for 2 years, with the latest figure at $400000.0 in Q4 2017.
- For the quarter ending Q4 2017, Depreciation and Depletion fell 20.0% year-over-year to $400000.0; the trailing twelve-month figure through Dec 2017 stood at $1.7 million (changed N/A YoY), and the FY2025 full-year result was $1.2 million, down 25.0% from the prior year.
- Depreciation and Depletion for Q4 2017 stood at $400000.0, up from $368000.0 in the prior quarter.
- The five-year high for Depreciation and Depletion was $500000.0 in Q4 2016, with the low at $368000.0 in Q3 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation and Depletion (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1,395.22 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | CytomX Therapeutics | 520.30 Mn | 173.59 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | 400,000.00 |
| Dec 31, 2017 | 400,000.00 |
| Sep 30, 2017 | 368,000.00 |
| Sep 30, 2017 | 368,000.00 |
| Dec 31, 2016 | 500,000.00 |
| Dec 31, 2016 | 500,000.00 |
| Sep 30, 2016 | 443,000.00 |
| Sep 30, 2016 | 443,000.00 |